Joël Jean-Mairet, PhD
Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche in 2005. Joël is currently on the Boards of Aura Biosciences Inc., AM-Pharma B.V., BioClin Therapeutics Inc. and Chairman of Inbiomotion S.L. He has been Chairman of the Board of Cellerix (now Tigenix NYSE Euronext TIG), Board member of Tigenix N.V., Medlumics S.L., Dermalumics S.L. and Board Observer at Boston-based Biovex Inc. (now Amgen). He has earned numerous awards, including the Wall Street Journal Europe Innovation Award in 2001. Joël holds a master degree in Biotechnology and earned his PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.